SUPRAX 100 MG / 5 ML — DIN 00868965
CEFIXIME : 100 MG / 5 ML · ODAN LABORATORIES LTD · POWDER FOR SUSPENSION · wholesale supply in Canada
Health Canada status: MARKETED
What is SUPRAX?
SUPRAX 100 MG / 5 ML contains CEFIXIME : 100 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 00868965, held by ODAN LABORATORIES LTD, supplied as POWDER FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 14-Jul-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SUPRAX used for?
SUPRAX (cefixime) is indicated in the treatment of infections caused by susceptible strains of designated microorganisms in the upper respiratory tract (pharyngitis and tonsillitis), middle ear (otitis media), paranasal sinuses (sinusitis), lower respiratory tract (acute bronchitis), urinary tract (acute uncomplicated cystitis and urethritis), and uncomplicated gonorrhea.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cefixime cost around the world?
Cefixime is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 33 | 33 | SAR███.██ |
| Bahrain | retail (max) | 9 | 23 | BHD███.██ |
| United States | acquisition | 3 | 7 | USD███.██ |
| South Africa | single exit price | 2 | 5 | ZAR███.██ |
| Hungary | producer price (ex-factory) | 3 | 3 | HUF███.██ |
| Morocco | PPV (public price) | 1 | 3 | MAD███.██ |
| United Arab Emirates | public | 2 | 2 | AED███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| United Kingdom | hospital | 1 | 1 | GBP███.██ |
79 pack listings across 56 brand entries and 7 price bases, refreshed 05 Sep 2026. Ranges span every Cefixime pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Cefixime in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Cefixime, across 8 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AURO PHARMA INC | 2 | 2 | AURO-CEFIXIME | Sourceable in Canada |
| ODAN LABORATORIES LTD | 2 | 2 | SUPRAX | Sourceable in Canada |
| AVENTIS PHARMA INC | 2 | 0 | SUPRAX | No marketed DIN |
| RHONE-POULENC RORER CANADA INC. | 1 | 0 | SUPRAX - TAB 200MG | No marketed DIN |
| SANOFI-AVENTIS CANADA INC | 1 | 0 | SUPRAX | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG / 5 ML |
|---|---|
| Dosage form | POWDER FOR SUSPENSION |
| Route | ORAL |
| Pack configuration (monograph) | Blister packs of 7 tablets; Blister packs of 10 tablets; powder for oral suspension in bottles containing cefixime as trihydrate, corresponding to 1 g cefixime anhydrous (50 mL of suspension once reconstituted) |
| Storage | Stored at controlled room temperature 15 - 30 °C |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Cefixime |
|---|---|
| ATC code | J01DD08 |
| AHFS class | 08:12.06.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00868965 |
|---|---|
| DIN (unpadded, as printed on some documents) | 868965 |
| Brand name | SUPRAX |
| Generic / active ingredient | CEFIXIME : 100 MG / 5 ML |
| Market authorization holder | ODAN LABORATORIES LTD |
| Health Canada schedule | Prescription |
| ATC code | J01DD08 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01DD |
| Current status | MARKETED |
| Status date | 14-Jul-2017 |
| Original market date | 1990-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 8 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-CEFIXIME | 100 MG / 5 ML | POWDER FOR SUSPENSION | AURO PHARMA INC | MARKETED | 02468689 |
| AURO-CEFIXIME | 400 MG | TABLET | AURO PHARMA INC | MARKETED | 02432773 |
| SUPRAX | 400 MG | TABLET | ODAN LABORATORIES LTD | MARKETED | 00868981 |
| SUPRAX | 400 MG | TABLET | AVENTIS PHARMA INC | CANCELLED POST MARKET | 02195984 |
| SUPRAX | 200 MG | TABLET | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 00868973 |
| SUPRAX | 100 MG / 5 ML | POWDER FOR SOLUTION | AVENTIS PHARMA INC | CANCELLED POST MARKET | 02195992 |
| SUPRAX - TAB 200MG | 200 MG | TABLET | RHONE-POULENC RORER CANADA INC. | CANCELLED POST MARKET | 02195976 |
2 · Same class — other molecules in ATC J01DD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ceftriaxone | CEFTRIAXONE FOR INJECTION · CEFTRIAXONE FOR INJECTION USP · CEFTRIAXONE INJECTION, USP · CEFTRIAXONE SODIUM FOR INJECTION · +7 more | 41 | 13 | Yes |
| Ceftazidime | CEFTAZIDIME FOR INJECTION BP · CEFTAZIDIME FOR INJECTION, BP · CEFTAZIDIME FOR INJECTION, USP · CEPTAZ INJ 10GM/VIAL · +13 more | 23 | 6 | Yes |
| Cefixime | AURO-CEFIXIME · SUPRAX · SUPRAX - TAB 200MG | 8 | 4 | Yes |
| Cefotaxime | CEFOTAXIME SODIUM FOR INJECTION BP · CEFOTAXIME SODIUM FOR INJECTION, BP · CLAFORAN - PWS INJ 1.0G/VIAL · CLAFORAN - PWS INJ 2.0G/VIAL · +9 more | 21 | 2 | Yes |
| Ceftizoxime | CEFIZOX | 2 | 0 | Not in Canada |
| Cefpodoxime | ORELOX | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01DB | Cefadroxil · Cefalexin · Cefalotin · Cefazolin | 91 | 41 |
| J01DH | Doripenem · Ertapenem · Imipenem And Cilastatin · Meropenem · Meropenem And Vaborbactam | 51 | 24 |
| J01DC | Cefaclor · Cefamandole · Cefotetan · Cefoxitin · Cefprozil · +1 more | 135 | 18 |
| J01DE | Cefepime | 10 | 3 |
| J01DF | Aztreonam | 1 | 1 |
| J01DI | Ceftobiprole Medocaril · Ceftolozane And Beta-Lactamase Inhibitor | 2 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is SUPRAX called?
Also recorded in Canada as: cefixime 400 MG Oral Capsule [Suprax] (US), cefixime 20 MG/ML Oral Suspension [Suprax] (US), cefixime 100 MG/ML Oral Suspension (US), cefixime 200 MG Oral Tablet (US), cefixime 400 MG Oral Tablet (US), cefixime 20 MG/ML Oral Suspension (US), cefixime 400 MG Oral Capsule (US), cefixime 40 MG/ML Oral Suspension (US), CEFIXIME (US), CEFIXIME 400 MG (US).
The same molecule, Cefixime, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Mixif | Latin | Bahrain, Saudi Arabia |
| CEFIX | Latin | Bahrain |
| MAGNACEF | Latin | Bahrain |
| OROKEN | Latin | Morocco |
| WINEX | Latin | Bahrain |
| Exsef | Latin | South Africa |
| CEFIM | Latin | Bahrain |
| SUPRAX DS | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.